Skip to main content
. 2021 Oct 20;9(10):e002684. doi: 10.1136/jitc-2021-002684

Figure 2.

Figure 2

Immune cell density and activity within primary lung tumors and BrMs. (A) Representative images of primary lung tumors and BrMs. H&E images are provided for reference in addition to fluorescence panels showing immune cell subsets. (B) Immune cell infiltration was significantly lower in BrMs compared with primary lung tumors as measured by visual assessment (TIL) or QIF of CD3+ T cells (p<0.0001), CD4+ helper cells (p=0.0416), CD8+ effector cells (p=0.0003), CD20+ B cells (p=0.0058), and FOXP3+CD4+ regulatory T cells (p=0.0002). Expression is displayed as ratios normalized to the average expression in the lung. (C) GZB expression in CD3+ T cells was also significantly lower in BrMs compared with primary lung (p=0.019), as measured by QIF. Ki67 expression, a measure of proliferation, was not significantly different between primary lung tumors or BrMs (p=0.944). (D) High CD3+ T cells in BrMs were associated with longer survival (p<0.0001). The median cutpoint was used to define high/low expression. *p<0.05. BrM, brain metastasis; GZB, granzyme B; QIF, quantitative immunofluorescence; TIL, tumor-infiltrating lymphocyte.